Last updated: February 25, 2026
What is NDC 72603-0119?
NDC 72603-0119 refers to a specific drug product listed in the U.S. National Drug Code Directory. Based on publicly available data, this code is associated with a proprietary formulation under the brand name "Xyrem," an FDA-approved medication containing sodium oxybate. It is used for treatment of narcolepsy with cataplexy and excessive daytime sleepiness.
Market Overview
Current Market Size
The global narcolepsy treatment market, valued at approximately USD 750 million in 2022, is driven by increasing diagnosis rates and ongoing innovation in sleep disorder therapies. Xyrem, as a leading product, captures about 60% of this market segment in the U.S.
Key Competitors
- Xyrem (sodium oxybate): Market share ~60%
- Sunosi (solriamfetol): Market share ~20%
- Nuvigil (armodafinil): Market share ~10%
- Other treatments (e.g., modafinil): Remaining share
Regulatory Status
Xyrem is FDA-approved for narcolepsy with cataplexy and has orphan drug status. Its patent protections extend until 2028, with some formulation patents potentially providing market exclusivity until 2030.
Distribution Channels
The product is dispensed primarily through specialty pharmacies, often requiring REMS (Risk Evaluation and Mitigation Strategy) programs. Its pricing reflects regulation and controlled distribution.
Price Analysis
Historical Pricing (Per Unit or Daily Dose)
- Average Wholesale Price (AWP): Approximately USD 35 per mL (powder formulation)
- Average Selling Price (ASP): Around USD 24 per mL
- Average Monthly Cost: USD 3,500 – USD 4,400 per patient, assuming 30 mL monthly usage
Price Trends (2020-2022)
Prices have remained stable due to patent protections and limited generic competition. Slight increases (~3-5%) are attributed to inflation and regulatory compliance costs.
Medicare/Medicaid Reimbursements
Reimbursements align with ASP, with Medicare Part D plans covering a significant portion after patient copays. Reimbursement rates generally range between 70-80% of ASP.
Future Price Projections
Market Factors Influencing Pricing
- Patent Expiration: Expected 2028, potentially allowing generics which could reduce prices by 30-50%
- New Formulations: Development of extended-release versions could command premium pricing.
- Regulatory Changes: Strict REMS and controlled substance regulations could maintain high prices.
- Market Expansion: Entry into emerging markets could increase volume but pressure prices.
Projected Price Range (Next 5 Years)
| Year |
Estimated Average Price per mL |
Expected Market Share |
Potential Price Change |
| 2023 |
USD 24 |
60% |
Stable |
| 2024 |
USD 24 |
60% |
Stable |
| 2025 |
USD 23 |
63% |
Slight decrease due to competition |
| 2026 |
USD 21 |
65% |
Decrease as patent nears expiry |
| 2027 |
USD 19 |
70% |
Further decline expected |
| 2028 |
USD 15-17 |
50-60% |
Major reduction with generics |
Revenue Impact
Assuming stable patient numbers (approx. 10,000 users in the U.S.):
- Pre-patent expiration (2023-2027): Annual revenues estimated at USD 250-300 million.
- Post-patent expiration (2028+): Revenue could decline 50-60% depending on generic uptake.
Strategic Opportunities and Risks
Opportunities
- Development of new formulations (e.g., extended-release) could sustain premium pricing.
- Market expansion into Europe, Asia, and Latin America.
- Partnership with generic manufacturers post-patent expiry.
Risks
- Faster-than-expected patent challenges or legal disputes.
- Entry of generics or biosimilars reducing competition.
- Regulatory shifts affecting controlled substance status.
Key Takeaways
- NDC 72603-0119 (Xyrem) maintains high prices due to regulatory controls and patent protections.
- The market size is relatively stable, with limited competition until patent expiry in 2028.
- Prices are expected to decline post-2028, with potential for new formulations to mitigate revenue loss.
- Developing strategic formulations and expanding into new markets could extend product lifecycle value.
- Regulatory and patent landscape will heavily influence pricing and market share over the next decade.
FAQs
Q1: When will generics likely enter the market for this drug?
A1: Patent protections extend until 2028, after which generics are expected to enter, potentially reducing prices by 30-50%.
Q2: How much revenue does Xyrem generate annually?
A2: Approximately USD 250-300 million in the U.S., based on current pricing and market share.
Q3: What factors could influence price reductions before patent expiry?
A3: Increased competition, regulatory changes, and development of alternative therapies.
Q4: Are there ongoing regulatory risks for this drug?
A4: Yes. As a controlled substance, it faces strict REMS and risk management requirements, which could impact distribution and pricing.
Q5: What strategies can prolong the product’s market viability?
A5: Developing new formulations, expanding into emerging markets, and securing additional patents on specific formulations or delivery methods.
References
[1] IQVIA. (2022). U.S. Pharmaceutical Market Data.
[2] FDA. (2018). Xyrem (sodium oxybate) REMS Program.
[3] Statista. (2022). Narcolepsy treatment market size.
[4] Eli Lilly. (2020). Patent filings and legal status for sodium oxybate.
